Pfizer
Business & Industry
- U.S. FDA grants full approval to Pfizer's BRAFTOVI combination regimen in first-line metastatic colorectal cancer
- Pfizer launches cost savings program on TrumpRx lowering drug costs for millions of Americans
- Sanofi announces the signing of a share buyback mandate for up to €1 billion
- AstraZeneca begins trading on the New York Stock Exchange
- Abbott increases quarterly dividend for 54th consecutive year
Research & Development
- New antibody-drug conjugate strategy to block HIV infection
- Rhododendron-derived drugs now made by bacteria
- Lung cancer drug offers a surprising new treatment against ovarian cancer
- Researchers identify promising Alzheimer's disease drug target
- Repurposed alcoholism drug fights liver cancer by targeting fat metabolism and blood supply
- Integrating heart imaging and proteomics identifies drug targets for cardiovascular diseases
- Multiple myeloma: Established cancer drug reactivates immunotherapy
Conferences & Events
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
- CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
- CPHI Frankfurt 2022: Global pharma confidence hits record high in the annual CPHI Pharma Index
Regulatory Affairs
- FDA expands artificial intelligence capabilities with agentic AI deployment
- FDA approves first gene therapy for treatment of aromatic L-amino acid decarboxylase deficiency
- FDA approves new treatment for hemophilia A or B
- FDA approves nasal spray influenza vaccine for self- or caregiver-administration
- FDA approves first nasal spray for treatment of anaphylaxis